Overview
Microbiota Restoration for Reduction of Recurrent C. difficile Infection - Understanding the Human Gut Microbiota
Role of the gut microbiome in C. difficile infection
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Faculty review unmet clinical needs in the context of available therapies and guidelines for reducing recurrent C. difficile. The role of the gut microbiome in C. difficile infection and emerging approaches to restoration as a means to break the cycle of recurrent C. difficile are also discussed.
This activity is intended for ID specialists, hospitalists, internists, physicians, pharmacists and other clinicians who care for patients at risk of serious infection.
This enduring activity reviews the role of the gut microbiome in C. difficile infection and introduce emerging approaches to restoration to reduce complications and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
• Identify the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Restate guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
• Identify the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Restate guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
AGENDA
Welcome & Introductions
The Changing Epidemiology and Treatment of C. difficile – Dr. Paul Feuerstadt
Role of the Gut Microbiome – Dr. Teena Chopra
Breaking the Cycle of Recurrence – Dr. Sahil Khanna
Welcome & Introductions
The Changing Epidemiology and Treatment of C. difficile – Dr. Paul Feuerstadt
Role of the Gut Microbiome – Dr. Teena Chopra
Breaking the Cycle of Recurrence – Dr. Sahil Khanna
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Ferring Pharmaceuticals, Inc
Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA
Associate Professor of Medicine, Division of Infectious Diseases
Corporate Medical Director, Infection Prevention, Epidemiology, and Antibiotic Stewardship
Wayne State University
Detroit Medical Center
Director, Infection Prevention, Epidemiology and Antibiotic Stewardship
Vibra Hospital
Detroit, MI
Associate Professor of Medicine, Division of Infectious Diseases
Corporate Medical Director, Infection Prevention, Epidemiology, and Antibiotic Stewardship
Wayne State University
Detroit Medical Center
Director, Infection Prevention, Epidemiology and Antibiotic Stewardship
Vibra Hospital
Detroit, MI
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Sahil Khanna, MBBS, MS
Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Teena Chopra, MD, MPH
Speakers Bureau: Allergan, Cepheid, Melinta Therapeutics, Inc., Merck & Company, Pfizer
Consulting Agreements: Cepheid, Shionogi, Inc.
Data and Safety Monitoring Board Chari (DSMB): Ferring Pharmaceuticals, Inc.
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Sahil Khanna, MBBS, MS
Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Partial credit may not be awarded for pharmacy credit; participation in the complete activity is required to receive credit.
Partial credit may not be awarded for pharmacy credit; participation in the complete activity is required to receive credit.
For questions, contact Melissa Stradal at 773-714-0705 x160
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.0 contact hour.
ACPE Universal Activity Number: 0396-0000-19-080-H01-P
Activity Type(s): Knowledge
This activity has been approved for 1.0 contact hour.
ACPE Universal Activity Number: 0396-0000-19-080-H01-P
Activity Type(s): Knowledge
